Enochian Biosciences, Inc (ENOB)

Etorro trading 970x250
Enochian Biosciences, Inc (ENOB) Logo

About Enochian Biosciences, Inc

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company’s lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company’s pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California. Address: Century City Medical Plaza, Los Angeles, CA, United States, 90067-2012

Enochian Biosciences, Inc News and around…

Latest news about Enochian Biosciences, Inc (ENOB) common stock and company :

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
18 Oct, 2021 Yahoo! Finance

Company encouraged by clear path to IND in near-term following its review of the FDA’s Center for Biologics Evaluation and Research written commentsLOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Investigator Pre-Investigational New Drug (IND) process following receipt of written comments from the U.S. Food and Drug A

Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
15 Oct, 2021 Yahoo! Finance

LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Peter Piot has resigned as Chairperson of the Respiratory Diseases Scientific Advisory Board due to important responsibilities advising a major governmental organization on COVID-19 that creates a conflict. “I remain very impressed by, and enthusiastic about, the innovative science and potenti

12 Health Care Stocks Moving In Friday's Intraday Session
15 Oct, 2021 FinancialContent

Gainers Statera BioPharma (NASDAQ:STAB) shares rose 16.9% to $3.32 during Friday's regular session. The market value ...

Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
12 Oct, 2021 Yahoo! Finance

LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference. Dr. Mark Dybul, CEO will participate in a Fireside Chat with H.C. Wainwright’s Patrick Trucchio, Managing Director and Senior Healthcare Analyst to discuss Enochian BioScienc

12 Health Care Stocks Moving In Thursday's Pre-Market Session
30 Sep, 2021 FinancialContent

Gainers OptimizeRx (NASDAQ:OPRX) stock increased by 12.12% to $84.05 during Thursday's pre-market session. The ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
28 Sep, 2021 FinancialContent

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 35.02% to $7.22 during Tuesday's regular session. ...

Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
27 Sep, 2021 FinancialContent

Company encouraged by clear path following review of FDA’s CBER written comments

Is Enochian Biosciences (NASDAQ:ENOB) Using Debt In A Risky Way?
26 Sep, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
14 Sep, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock rose 20.19% to $1.13 during Tuesday's pre-market session. The company's ...

Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference
13 Sep, 2021 FinancialContent
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
30 Aug, 2021 FinancialContent
12 Health Care Stocks Moving In Thursday's After-Market Session
26 Aug, 2021 FinancialContent

Gainers MorphoSys (NASDAQ:MOR) stock moved upwards by 15.07% to $16.26 during Thursday's after-market session. The market value of ...

Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board
23 Aug, 2021 FinancialContent
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
20 Jul, 2021 FinancialContent

Dr. Dybul’s Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences’ Scientific Approach

Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program
12 Jul, 2021 FinancialContent

Enochian BioSciences Inc(NASDAQ: ENOB) hasannounced that the FDA has accepteda Pre-IND (Investigational New Drug) ...

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
12 Jul, 2021 FinancialContent
Enochian Gains As FDA Agrees To Give View On Potential Cure For Hepatitis B
12 Jul, 2021 Yahoo! Finance

By Dhirendra Tripathi

12 Health Care Stocks Moving In Friday's Pre-Market Session
09 Jul, 2021 FinancialContent

Gainers Galectin Therapeutics (NASDAQ:GALT) shares moved upwards by 47.46% to $4.07 during Friday's pre-market ...

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
30 Jun, 2021 FinancialContent
Why Enochian BioSciences Was a Winner on Monday
21 Jun, 2021 FinancialContent

The company scores an exclusive license for new potential coronavirus treatment technology.

4 Stocks to Boost Your Portfolio (In an Unintuitive Way)
21 Jun, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Moonshot investing can be risky, that's for sure. But if you learn from the mistakes of past moonshots, you can minimize your own. The post 4 Stocks to Boost Your Portfolio (In an Unintuitive Way) appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

Why Enochian Biosciences, Raven Industries And GE Share Are Trading Higher Today
21 Jun, 2021 FinancialContent

Enochian Biosciences Inc (NASDAQ: ENOB) shares are trading higher by 11.7% at $6.48 Monday morning after the company announced it ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
21 Jun, 2021 FinancialContent

Gainers MediciNova (NASDAQ:MNOV) shares moved upwards by 50.79% to $5.67 during Monday's pre-market session. The ...

Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology
21 Jun, 2021 FinancialContent

Enochian BioSciences Inc(NASDAQ: ENOB) has acquired anexclusive license for a technologyto potentially treat and ...

Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology
21 Jun, 2021 FinancialContent

Request for Pre-Investigator New Drug Meeting to Be Submitted to FDA in Near Term

Pioneering Research Institute In Los Angeles Moves One Step Closer To Finding A Cure For HIV
15 Jun, 2021 Yahoo! Finance

(NASDAQ: ENOB) – A promising cure for HIV is moving one step closer to FDA approval. The novel approach to treating HIV in humans using cell therapy, developed by Dr. Serhat Gumrukcu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his team, will move forward to the first stage of the approval process with the FDA – a Pre-Investigational New Drug (Pre-IND) meeting.

The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
15 Jun, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

60 Biggest Movers From Yesterday
15 Jun, 2021 FinancialContent

Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced ...

Here's Why Enochian BioSciences Stock Skyrocketed Today
14 Jun, 2021 FinancialContent

The biotech's experimental treatment for HIV could be a game changer.

Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
14 Jun, 2021 FinancialContent

Enochian Biosciences, Inc (ENOB) is a NASDAQ Common Stock listed in , ,

970x250